Cytokinetics Stock News

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scienti

Cytokinetics Incorporated (NASDAQ:CYTK) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.98% to the previous day’s close as strong demand from buyers drove the stock to $37.50. Actively observing the price movement in the last trading, the stock closed the session at $37.87, falling within a range of $37.08 and … Cytokinetics Incorporated (NASDAQ: CYTK) Shares Are Set To Rise By 2022 Read More »

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 11:20 am ET and participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 11:45 am ET at the Loews Miami Beach Hotel in Miami Beach.

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pr

Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2022 it granted stock options to purchase an aggregate

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) an

Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q4 2021 Results - Earnings Call Transcript

Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics press release (CYTK): Q4 GAAP EPS of -$0.36 beats by $0.51.Revenue of $55.6M (+727.4% Y/Y) beats by $50.04M.Cash, cash equivalents and investments totaled $623.7 million…

Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil in Advance of PDUFA Date of November 30, 2022

Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?